Mutagen exposures and chromosome 3 aberrations in acute myelocytic leukemia

Leukemia

Volumn 14, Issue 1, 2000, Pages 112-118

  Lindquist, R ^a   Forsblom, A M ^a   Ost A ^b   Gahrton, G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acute myeloid leukemia; Chromosome, fragile site; Chromosomes 3; Megakaryocyte; Mutagen exposure; Occupational exposure

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; MUTAGENIC AGENT; ORGANIC SOLVENT; PETROLEUM DERIVATIVE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHROMOSOME 3; CHROMOSOME ABERRATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; INTERSTITIAL CHROMOSOME DELETION; IRRADIATION; KARYOTYPE; MALE; MONOSOMY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; STRUCTURAL CHROMOSOME ABERRATION; TRISOMY;

EID: 0033967382     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401622     Document Type: Article

References (74)

1. Devald G. Fourth International Workshop on Chromosomes in Leukemia 1982: abnormalities of chromosome 3 among 24 patients with de novo ANLL. Cancer Genet Cytogenet 1984; 11: 306.
2. Mitelman F. Chromosomes 1-12. Catalog of Chromosome Aberrations in Cancer, 5th edn. Wiley-Liss: New York, 1994, pp 439-489.
3. Heim S, Mitelman F. Chromosomal and molecular genetic aberrations of tumor cells. Cancer Cytogenetics, 2nd edn. Alan R Liss: New York, 1995, pp 69-140.
4. Smith DI, Glover TW, Gemmill R, Drabkin H, O'Connell P, Naylor SL. Report of the Fifth International Workshop on Human Chromosome 3 mapping 1994. Cytogenet Cell Genet 1995; 68: 125-136.
5. Sweet DL. Acute myelocytic leukemia and thrombocythemia associated with an abnormality of chromosome No. 3. Cancer Genet Cytogenet 1979; 1: 33-37.
6. Bernstein R, Pinto MR, Behr A, Medelow B. Chromosome 3 abnormalities in acute nonlymphocytic leukemia (ANLL) with abnormal thrombopoiesis: reports of three patients with a 'new' inversion anomaly and a further case of homologous translocation. Blood 1982; 60: 613-617.
7. Mecucci C, Van Den Berghe H. Thrombocytosis and inv(3)(q21q26). Blood 1983, 61: 1027.
8. Carbonell F, Hoelzer D, Thiel E, Bartle R. Ph1-positive CML associated with megakaryocylic hyperplasia and thrombocythemia and an abnormality of chromosome no. 3. Cancer Genet Cytogenet 1982; 6: 153-161.
9. Bernstein R, Bagg A, Pinto M, Lewis D, Mendelow B. Chromosome 3q21 abnormalities associated with hyperactive thrombopoiesis in acute blastic transformation of chronic myeloid leukemia. Blood 1986; 68: 652-657.
10. Mertens F, Johansson B, Billström R, Engquist L, Mitelman F. A case of myelodysplastic syndrome with high platelet counts and a t(3;8)(q26;q24). Cancer Genet Cytogenet 1987; 27: 1-4.
11. Norrby A, Riddell B, Swolin B, Westin J. Rearrangement of chromosome No. 3 in a case of preleukemia with thrombocytosis. Cancer Genet Cytogenet 1981; 5: 257-263.
12. Pedersen-Bjergaard J, Pedersen M, Roulstow D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
13. Rynditch A, Pekarsky Y, Snittger S, Gardiner K. Leukemia breakpoint region in 3q21 is gene rich. Gene 1997; 193: 49-57.
14. International Agency for Research on Cancer (IARC). On the evaluation of carcinogenic risks to humans: some organic solvents, resin monomers and related compounds, pigments and occupational exposures in paint manufacture and painting. Some petroleum solvents. 1989; 47: 43-77. Occupational exposures in paint manufacture and painting 1989; 47: 329-442. World Health Organization (WHO): Lyon, France.
15. International Agency for Research on Cancer (IARC). On the evaluation of carcinogenic risks to humans: some organic solvents, resin monomers and related compounds, pigments and occupational exposures in paint manufacture and painting. Some petroleum solvents. 1989; 47: 43-77. Occupational exposures in paint manufacture and painting 1989; 47: 329-442. World Health Organization (WHO): Lyon, France.
16. International Agency for Research on Cancer (IARC). On the evaluation of carcinogenic risks to humans: Diesel and gasoline engine exhausts and some nitroarenes. Diesel and gasoline engine exhausts. 1989; 46: 41-185. World Health Organization (WHO): Lyon, France.
17. International Agency for Research on Cancer (IARC). On the evaluation of carcinogenic risks to humans: Occupational exposures in petroleum refining; Crude oil and major petroleum fuels. General remarks. 1989; 45: 31-36. Gasoline. 1989; 45: 159-201. Diesel fuels. 1989; 45: 219-237. World Health Organization (WHO): Lyon, France.
18. International Agency for Research on Cancer (IARC). On the evaluation of carcinogenic risks to humans: Occupational exposures in petroleum refining; Crude oil and major petroleum fuels. General remarks. 1989; 45: 31-36. Gasoline. 1989; 45: 159-201. Diesel fuels. 1989; 45: 219-237. World Health Organization (WHO): Lyon, France.
19. International Agency for Research on Cancer (IARC). On the evaluation of carcinogenic risks to humans: Occupational exposures in petroleum refining; Crude oil and major petroleum fuels. General remarks. 1989; 45: 31-36. Gasoline. 1989; 45: 159-201. Diesel fuels. 1989; 45: 219-237. World Health Organization (WHO): Lyon, France.
20. Lindquist R, Nilsson B, Eklund G, Gahrton G. Increased risk of developing acute leukemia after employment as a painter. Cancer 1987; 60: 1378-1384.
21. Lindquist R, Nilsson B, Gahrton G, Eklund G. Acute leukemia and exposure to petroleum products in drivers. Eur J Hematol 1991; 47: 98-103.
22. Paul C, Björkholm M, Christenson I, Engstedt L, Gahrton G, Johansson B, Järnmark M, Killander A, Lindemalm C, Lindquist R, Lockner D, Lönnkvist B, Mellstedt H, Merk K, Palmblad J, Peterson C, Sinionsson B, Stalfelt A-M, Sundström C, Wadman B, Wedelin C, Udén A-M, Ahre A, Oberg G, Öst A. Induction and intensive consolidation in acute nonlymphoblastic leukemia (ANLL) with combinations containing doxorubic in-DNA. Prolonged remission duration and survival. In: Lectures and Symposia 14th International Cancer Congress, Budapest. Eckhardt L (ed). Biological response modifiers. Leuk Lymphomas 1986; 10: 101-108.
23. Paul C, Tidefelt U, Gahrton G, Björkholm M, Järnmark M, Killander A, Kimby E, Liliemark E, Liliemark J, Lindeberg A, Lindquist R, Lockner D, Lönnqvist B, Mellstedt H, Merk K, Palmblad J, Peterson C, Simonsson B, Stalfelt A-M, Sundström C, Wadman B, Wedelin C, Udén A-M, Öberg G, Öst A. A randomized comparison of cloxorubic in and doxorubic in-DNA in the treatment of acute nonlymphoblastic leukemia. Leuk Lymphoma 1991; 3: 355-364.
24. Tjou JH, Wang J. Chromosome preparations of bone marrow cells without prior in vitro culture or in vivo colchicine administration. Stain Technol 1962; 37: 17-20.
25. Caspersson T, Lomakka G, Zech L. The fluorescence patterns of the human metaphase chromosome - distinguishing characters and variability. Hereditas 1971; 67: 89-102.
26. ISCN. An International System for Human Cytogenetic Nomenclature. Mitelman F (ed). S Karger: Basel, 1995.
27. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of the acute leukemias. Br J Haematol 1976; 44: 451-458.
28. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocytic lineage (M7). Ann Intern Med 1985; 103: 460-462.
29. Öst Å, Lagerlöf B, Sundström C. A study of reproducibility of the diagnostic criteria for acute leukemia. Scand J Haematol 1988; 31: 257-266.
30. Infante PF, Rinsky RA, Wagoner JK, Young RJ. Leukemia in benzene workers. Lancet 1977; 2: 76-78.
31. Brandt L, Nilsson PG, Mitelman F. Occupational exposure to petroleum products in men with acute nonlymphocytic leukemia. Br Med J 1978; 4: 553.
32. International Programme on Chemical Safety (IPCS). World Health Organization (WHO), Geneva. Environmental Health Criteria. 150. Benzene. Ed. EE McConnell Summary and conclusions. 1993 pp 13-8. Sources of human and environmental exposure. pp 28-31.
33. International Programme on Chemical Safety (IPCS). World Health Organization (WHO), Geneva. Environmental Health Criteria. 150. Benzene. Ed. EE McConnell Summary and conclusions. 1993 pp 13-8. Sources of human and environmental exposure. pp 28-31.
34. Smith MT. The mechanism of benzene-induced leukemia: a hypothesis and speculations on the causes of leukemia. Environ Health Perspect 1996; 104: 1219-2226.
35. Smith MT, Fanning EW. Report on the workshop entitled: 'Modeling chemically induced leukemia - implications for benzene risk assessment.' Leukemia Res 1997; 21: 361-374.
36. Snyder R, Hedli CC. An overview of benzene metabolism. Environ Health Perspect 1996; 104: 1165-1171.
37. Oshimura M, Barrett JC. Chemically induced aneuploidy in mammalian cells: mechanisms and biological significance in cancer. Environ Mutagen 1986; 8: 129-159.
38. Dekaban A. Persisting clone of cells with an abnormal chromosome in a woman previously irradiated. J Nucl Med 1965; 6: 740-746.
39. Sutherland GR. Fragile sites on human chromosomes: demonstrations of their dependence on the type of tissue culture medium. Science 1977; 197: 265-266.
40. Sutherland GR. Heritable fragile sites on human chromosomes II. Distribution, phenotypic effects and cytogenetics. Am J Hum Genet 1979; 31: 136-148.
41. Yunis JJ, Soreng AC. Constitutional fragile sites and cancer. Science 1984; 226: 1099-1204.
42. Yunis J, Soreng AL, Bove A. Fragile sites are targets of diverse mutagens and carcinogens. Oncogene 1987; 1: 59-69.
43. Yunis JJ. Fragile sites and predisposition to leukemia and lymphoma. Cancer Genet Cytogenet 1984; 12: 85-88.
44. Shi G, Weh HJ, Martensen S, Seeger D, Hossfeld DK. 3p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloiel leukemia. Cytogenet Cell Genet 1996; 74: 295-299.
45. Johansson B, Billström R, Kristoffersson U, Akerman M, Garwicz S, Ahlgren T, Malm C, Mitelman F. Deletion of chromosome arm 3p in hematologic malignancies. Leukemia 1997; 11: 1207-1213.
46. Whang-Peng J, Kao-Shan CS, Lee ED. Specific chromosome defect associated with human small cell lung cancer. Deletion 3p(14-23). Science 1982; 215: 181-182.
47. Kok K, Osinga J, Carritt B, Davis MB, van der Hout AH, van der Veen AY, Landsvater RM, de Leij LFMH, Berendsen HH, Postmus PE, Poppema S, Buys CHCM. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 1987; 330: 578-581.
48. Drabkin HA, Bradley C, Hart I, Bleskan J, Li FP, Patterson D. Translocation of c-myc in the hereditary renal cell carcinoma associated with a t(3;8)(p14.2;q24.13) chromosomal translocation. Proc Natl Acad Sci USA 1985; 82: 6980-6984.
49. Teyssier JR, Hemry I, Dozier C, Ferre D, Adnet JJ, Pluot M, Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma, shift of the c-raf 1 locus. J Natl Cancer Inst 1986; 77: 1187-1191.
50. Boldog F, Arheden K, Imreh S, Strombeck B, Szekely L, Erlandsson R, Maresek Z, Sumegi J, Mitelman F, Klein G. Involvement of 3p deletions in sporadic and hereditary forms of renal cell carcinoma. Genes Chromosomes Cancer 1991; 3: 403-406.
51. Gebhart E, Bruderlein S, Augustus M, Siebert E, Feldner J, Schmidt W. Cytogenetic studies on human breast carcinomas. Breast Cancer Res Treat 1986; 8: 125-138.
52. Trent JM, Salmon SE. Karyotypic analysis of human ovarian carcinoma cells cloned in short term agar culture. Cancer Genet Cytogenet 1981; 3: 279-291.
53. Inoue H, Ishii H, Alder H, Snyder E, Druck T, Huebner K, Croce CM. Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci USA 1997; 94: 14584-14589.
54. Pennisi E. New gene forges link between fragile site and many cancers. Science 1996; 272: 649.
55. Fong KM, Bisterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giallone G, Gazdar AF, Minna JD. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 1997; 57: 2256-2257.
56. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD, Gazdar AF. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer pro-bands. Cancer Res 1997; 57: 3664-3668.
57. Baffa R, Veronese ML, Santoro R, Mandes B, Palazzo JP, Rugge M, Santoro E, Croce CM, Huebner K. Loss of FHIT expression in gastric carcinoma. Cancer Res 1998; 58: 4708-4714.
58. Shridhar R, Shridhar V, Wang X, Paradee W, Dugan M, Sarkar F, Wilke C, Glover TW, Vaitkevicius VK, Smith DI. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res 1996; 56: 4347-4350.
59. Sugimoto K, Yamada K, Miyagawa K, Hirai H, Oshimi K. Decreased or altered expression of the FHIT gene in human leukemias. Stem Cell 1997; 15: 223-228.
60. Hall P, Boice JD Jr, Berg G, Bjelkengren G, Ericsson UB, Hallquist A, Lidberg M, Lundell G, Mattsson A, Tennvall J, Wiklund K, Holm L-E. Leukemia incidence after iodine-131 exposure. Lancet 1992; 340: 1-4.
61. Alimena G, Cedrone M, Nanni M, De Cuia MR, Lo Coco F, De Sanctis V, Cimino G, Mancini M. Acute leukemia presenting a variant Ph chromosome with p190 expression, dup 3q and -7, developed after malignant lymphoma treated with alkylating agents and topoisomerase II inhibitors. Leukemia 1995; 9: 1483-1486.
62. Pintado T, Ferro MT, Sanroman C, Mayayo M, Larana JG. Clinical correlations of the 3q21;3q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 1985; 55: 535-541.
63. Horsman DE, Gascoyne RD, Barnett MJ. Acute leukemia with structural rearrengments of chromosome 3. Leuk Lymphoma 1995; 16: 369-377.
64. Battout S. Thrombopoietin. A review. Haemostasis 1997; 27: 1-8.
65. Suzukawa K, Satoh H, Taniwaki M, Yokota J, Morishita K. The human thrombopoietin gene is located on chromosome 3q26.33-q27, but is not transcriptionally activated in leukemia cells with 3q21 and 3q26 abnormalities (3q21q26 syndrome). Leukemia 1995; 9: 1328-1331.
66. Bouscary D, Fontenay-Roupie M, Chretien S, Hardy AC, Viguie F, Picard F, Melle J, Dreyfus F. Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome. Br J Haematol 1995; 91: 425-427.
67. Fichelson S, Dreyfus F, Berger R, Meile J, Bastard C, Miclea JM, Gisselbrecht S. EVI-1 expression in leukemic patients with rearrangements of the 3q25-q28 chromosomal region. Leukemia 1992; 6: 93-99.
68. Morishita K, Parganas E, William CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB, Ihle JN. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci USA 1992; 89: 3937-3941.
69. Rubin CM, Larson RA, Anastasi J, Winter JN, Thangavelu M, Vardiman JW, Rowley JD, Le Beau MM. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 1990; 76: 2594-2598.
70. Berger R, Bernheim A, Le Coniat M, Veccione D, Pacot A, Daniel M-T, Flandrin G. Abnormalities of the short arm of chromosome 12 in acute nonlymphocytic leukemia and dysmyelopoietic syndrome. Cancer Genet Cytogenet 1986; 19: 281-289.
71. Mimori K, Druck T, Inoue H, Alder H, Berk L, Mori M, Huebner K, Croce CM. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. Proc Natl Acad Sci USA 1999; 96: 7456-7461.
72. Sutherland GR, Baker E, Richards RI. Fragile sites still breaking. Trends Genet 1998; 14: 501-506.
73. Le Beau MM, Rassool FV, Neilly ME, Espinosa R III, Glover TW, Smith DI, McKeithan TW. Replication of a common fragile site, FRA3B, occurs late in S phase and is delayed further upon induction: implications for the mechanism of fragile site induction. Hum Mol Genet 1998; 7: 755-761.
74. Wang L, Darling J, Zhang JS, Huang H, Liu W, Smith DI. Allele-specific late replication and fragility of the most active common site, FRA3B. Hum Mol Genet 1999; 8: 431-437.